SLATE

Serial Number 88030324
Registration 6775121
700

Registration Progress

Application Filed
Jul 9, 2018
Under Examination
Feb 18, 2020
Approved for Publication
Dec 24, 2019
Published for Opposition
Dec 24, 2019
Registered
Jun 28, 2022

Basic Information

Serial Number
88030324
Registration Number
6775121
Filing Date
July 9, 2018
Registration Date
June 28, 2022
Published for Opposition
December 24, 2019
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 28, 2022
Registration
Registered
Classes
042

Rights Holder

GRITSTONE BIO, INC.

03
Address
5959 Horton Street, Suite 300
Emeryville, CA 94608

Ownership History

Gritstone Oncology, Inc.

Original Applicant
03
Emeryville, CA

Gritstone Oncology, Inc.

Owner at Publication
03
Emeryville, CA

GRITSTONE BIO, INC.

New Owner After Publication #1
03
Emeryville, CA

GRITSTONE BIO, INC.

Original Registrant
03
Emeryville, CA

Legal Representation

Attorney
Fidel Nwamu

USPTO Deadlines

Next Renewal Deadline
1087 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-28)
Due Date
June 28, 2028
Grace Period Ends
December 28, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

50 events
Date Code Type Description
Jun 28, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER
Jun 28, 2022 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 21, 2022 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 20, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 20, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
May 20, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
May 20, 2022 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 1, 2022 CNRT W SU - NON-FINAL ACTION - WRITTEN
Apr 1, 2022 GNRT O NON-FINAL ACTION E-MAILED
Apr 1, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 2, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 2, 2022 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Feb 8, 2022 EISU I TEAS STATEMENT OF USE RECEIVED
Feb 8, 2022 IUAF S USE AMENDMENT FILED
Aug 20, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 18, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 18, 2021 EXT3 S SOU EXTENSION 3 FILED
Aug 18, 2021 EX3G S SOU EXTENSION 3 GRANTED
Jun 23, 2021 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 18, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 16, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 16, 2021 EXT2 S SOU EXTENSION 2 FILED
Feb 16, 2021 EX2G S SOU EXTENSION 2 GRANTED
Aug 5, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 5, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 5, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 23, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 21, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 21, 2020 EXT1 S SOU EXTENSION 1 FILED
Jul 21, 2020 EX1G S SOU EXTENSION 1 GRANTED
Feb 18, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 24, 2019 PUBO A PUBLISHED FOR OPPOSITION
Dec 24, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 4, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 14, 2019 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 14, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 13, 2019 ALIE A ASSIGNED TO LIE
Apr 21, 2019 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 9, 2018 CNSL R SUSPENSION LETTER WRITTEN
Oct 9, 2018 GNSL S LETTER OF SUSPENSION E-MAILED
Oct 9, 2018 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 5, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 4, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 4, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 8, 2018 CNRT R NON-FINAL ACTION WRITTEN
Aug 8, 2018 GNRT F NON-FINAL ACTION E-MAILED
Aug 8, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2018 DOCK D ASSIGNED TO EXAMINER
Jul 13, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Conducting evaluations in the field of pharmaceuticals; pharmaceutical product development and evaluation services; pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients
First Use Anywhere: Sep 17, 2016
First Use in Commerce: Sep 17, 2016

Classification

International Classes
042